MONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal women with HR+/HER2- advanced breast cancer[1] Kisqali is the first CDK4/6 inhibitor to be studied in a Phase … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged breast cancer, MONALEESA-7, MONALEESA-7 trial, Novartis, premenopausal women
Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced mobility and irreversible joint damage[2] FUTURE 5 is the largest randomized controlled … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Cosentyx, FUTURE 5, FUTURE 5 study on psoriatic arthritis, Novartis, PSA
Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy Effect driven … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged ACZ885, MACE, major adverse cardiovascular events, Novartis, placebo
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged ACZ885, CANTOS, lung cancer, Novartis
New leader to drive the digital transformation Novartis has embarked upon BASEL, 28-Aug-2017 — /EuropaWire/ — Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury’s Argos, has been appointed to the new role of Chief Digital Officer, … Read the full press release
Posted in Pharma & Biotech, Switzerland
Tagged Bertrand Bodson, Joseph Jimenez, Novartis
Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global product, broad-spectrum antibiotic amoxicillin-clavulanic acid. The investment will bring 150 new jobs, more than doubling the number of employees at … Read the full press release
Posted in Investment, Pharma & Biotech, Slovenia
Tagged investment, LEK, Miro Cerar PhD, Novartis, Sandoz, Vojmir Urlep
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated levels of lipoprotein Lp(a) or ApoCIII, which is a potent regulator of triglycerides … Read the full press release
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100,000 monthly treatments to Kenya, Ethiopia and Lebanon* First-year learnings underline broader … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Switzerland
Tagged Dr. Jonathan Kiliko, Joseph Jimenez, Novartis, Novartis Access, Rwanda
Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle glaucoma Two-year safety and efficacy data from landmark COMPASS study … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland, Technology
Tagged AAO annual meeting, Alcon, CyPass® Micro-Stent, Eye care leader, Franck Leveiller, glaucoma, Novartis, Sergio Duplan
Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered patients’ need for rescue medication and had improved benefit-risk profile compared to Seretide, with … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged COPD, Novartis, Novartis' Ultibro® Breezhaler®, Seretide, Vasant Narasimhan
Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights leading pipeline of second generation immuno-oncology assets Confirms Sandoz on track for 10 biosimilar filings by … Read the full press release
Posted in Healthcare, Management, Pharma & Biotech, Switzerland
Tagged biosimilars, eye care, Joseph Jimenez, Novartis, oncology
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily tablet and oral suspension formulation designed for younger children who may … Read the full press release
OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd tillsätts som vd för Becton, Dickinson and Companys (BD) affärsenhet BD Nordics. Helena har över 20 års erfarenhet som chef inom farmaceutisk och medicinteknisk verksamhet hos välkända aktörer inom branschen, bland annat ResMed, … Read the full press release
Posted in Denmark, Healthcare, Management, News, Technology, United Kingdom
Tagged BD, Becton Dickinson, Eli Lilly, Helena Bragd, Johnson and Johnson, Novartis, ResMed
OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd has joined global medical technology leader Becton, Dickinson and Company (BD) as General Manager for the Nordic region. Helena brings more than 20 years of pharmaceutical- and med-tech leadership experience to the role, … Read the full press release
Posted in Healthcare, Management, News, Technology, United Kingdom
Tagged appointment, BD, Becton Dickinson, Eli Lilly, Healthcare, Helena Bragd, Johnson and Johnson, Medica Comms, medical technology, Novartis, ResMed
Ultibro® Breezhaler® met primary endpoint and demonstrated superiority to Seretide® in reducing COPD exacerbations during 52 weeks of treatment First large-scale study to confirm Ultibro Breezhaler is an effective steroid-free option that both reduces exacerbations and improves lung function in … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged COPD exacerbations, Novartis, Ultibro Breezhaler
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated significant improvement in health-related quality of life vs vemurafenib monotherapy in this … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional neuroendocrine tumors of GI or lung origin are rare forms of cancer with poor prognoses and … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged advanced nonfunctional gastrointestinal, Afinitor®, lung NET, Novartis
Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully human monoclonal antibody for relapsing remitting multiple sclerosis (RRMS) which targets CD20 and … Read the full press release
Posted in Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Gilenya®, GlaxoSmithKline plc (GSK), multiple sclerosis, Novartis, Ofatumumab
Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of Tasigna in newly-diagnosed CML patients seen in the pivotal ENESTnd study … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Bruno Strigini, chronic myeloid leukemia (CML), Dr. Andreas Hochhaus, Novartis, Tasigna
Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an incurable cancer of the plasma cells, a type of white blood cell … Read the full press release
Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus existing CLL treatments also had a higher overall response rate (84% vs 68%) compared to … Read the full press release
New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2] Additional data at WCD show the consistent negative health impact and economic burden of CSU, … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Chronic Spontaneous Urticaria (CSU), Novartis, Vasant Narasimhan, Xolair®
Promacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low platelet count[1], ITP can affect up to 5 in 100,000 children each year[2] and … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Bruno Strigini, chronic immune thrombocytopenia (ITP), James B. Bussel MD, Novartis, Promacta, US FDA
Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients with moderate-to-severe palmoplantar psoriasis achieved clear or almost clear skin on their palms and … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Cosentyx, Novartis, psoriasis, Vasant Narasimhan
Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at a major medical meeting; worldwide regulatory filings are planned for 2015 Afinitor is already … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged advanced gastrointestinal, Afinitor®, lung neuroendocrine tumors, Novartis
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies showed NVA237 provided significant and clinically meaningful improvements in lung function in moderate-to-severe COPD patients[8],[9] In … Read the full press release
New analysis will confirm high efficacy of Gilenya® in achieving ‘no evidence of disease activity’ (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding brain shrinkage to an existing assessment tool enhances ability to predict disability progression in … Read the full press release
Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with an overproduction of blood cells that can lead to serious cardiovascular complications … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Dr. Claire Harrison, hydroxyurea, Jakavi®, Novartis, polycythemia vera, the Pivotal Clinical Trial
Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] Nearly six million people live with heart failure in … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged David Epstein, FDA, investigational medicine, Novartis, treatment of heart failure
With today’s approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero’s two-dose regimen offers a flexible dosing schedule, with the first and second doses administered at least … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Andrin Oswald, Bexsero®, FDA, meningococcal disease caused by meningitis B, Novartis
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib) significantly improved hematocrit levels and reduced spleen size, key measures of disease control[2] … Read the full press release
Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR, a next-generation somatostatin analog, provides a new option for patients with acromegaly with inadequately controlled disease[2] Signifor LAR FDA approval is … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged acromegaly, Bruno Strigini, Dr. Monica Gadelha, FDA approval, hormonal disorder, Novartis, Signifor® LAR
Acromegaly is a rare pituitary disorder, which requires normalization of hormonal levels to help prevent the serious consequences of the disease[1],[2],[3],[4] Approval based on two large phase III trials showing superior efficacy of new formulation of Signifor over current SSAs … Read the full press release
CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influenza segments of Novartis Vaccines to GlaxoSmithKline Basel, Switzerland, 28-10-2014 — /EuropaWire/ — Novartis today … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged CSL, CSL Limited, Eric Althoff, influenza vaccines business, Joseph Jimenez, Liz Power, Novartis
Secukinumab met primary and key secondary endpoints in two pivotal Phase III studies showing superiority to placebo in patients with adult onset psoriatic arthritis (PsA) PsA is a debilitating, long-lasting condition that causes inflammation of joints and skin and affects … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland, Technology
Tagged AIN457 (secukinumab), Novartis, psoriatic arthritis, Vasant Narasimhan
KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years KAE609 was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 … Read the full press release
Novartis acquires exclusive ex-US rights to Fovista from Ophthotech; upfront payment of USD 200 million plus potential future recruitment and other milestone payments; additionally Ophthotech to receive royalties on ex-US Fovista sales Fovista is the most advanced anti-PDGF technology in … Read the full press release
Posted in Business, Management, Pharma & Biotech, Switzerland
Tagged David Epstein, Fovista®, Novartis, Ophthotech Corporation
Company is pleased to host second international conference dedicated to the research of rare and orphan diseases Novartis is engaging in public dialogue to help raise greater awareness of rare diseases and support for patients Company celebrates more than 50 … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Society, Switzerland
Tagged 2nd international conference of research of rare and orphan diseases, 6000 rare diseases, Ciba, Desferal®, Dr. Mark Fishman, EURORDIS, National Organization for Rare Disorders, Novartis, orphan diseases, Rare Disease Day, rare diseases, rare diseases area, rare hemopathies, RE(ACT) Congress 2014
Novartis announces that researchers can now request access to patient level data on newly approved innovative medicines in the United States and EU in 2014 through the Idea Point portal, and is committed to enhancing Clinical Study Report summaries for … Read the full press release
Posted in Healthcare, Management, Pharma & Biotech, Science, Switzerland
Tagged Clinical Study Reports, clinical trial data transparency, ClinicalTrials.gov, data transparency, innovative medicines, Novartis, Tim Wright, voluntarily disclosing summaries, voluntarily disclosing summaries of Clinical Study Reports
FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada Novartis is pursuing a US license that would allow immediate public health response to … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Andrin Oswald, bacterial infection, Bexsero®, Investigational New Drug (IND) designation, licensed broad coverage vaccine, Lynn Bozof, MenB, MenB outbreaks, meningococcal disease, Meningococcal Group B Vaccine, meningococcal serogroup B (MenB) vaccine, Novartis, Novartis Vaccines, protect against MenB, serogroup B, University of California Santa Barbara, US license for Bexsero, vaccination program
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
